Quantum-Si IncorporatedQuantum-Si IncorporatedQuantum-Si Incorporated

Quantum-Si Incorporated

No trades
See on Supercharts

Quantum-Si Incorporated stock forum

QSI 5 minimum on charts . Keep holding, those who did not DCA still chance

QSI should keep a solid uptrend in the short term

QSI load up we going 5.5 soon, all those who haven’t done DCA last chance

QSI I guess it’s safe to load in now that price target is buy and maintained at 5.5 by the analyst. Also the company has a buy back agreement at 3.25 so that’s the minimum safe passage. My advice DCA who ever did not and buy who ever has not bought and have some patience till Q4 earnings release.

QSI this got rise and fall due to name quantum where as it has nothing to do with same lol.. $5 still maintained target

QSI stock goes from monthly expirations to weekly with smaller spreads between strikes… low premiums .. currently..two separate share offerings in 2.20 range and 3.20 range to institutional investors… NVDA deal and looks as if the 1.00 min price for SEC obligations will be met by April… just a very interesting play

QSI just that you know if it covers gap down it does covers gap up aswell.. all the best mates..

QSI lol why people is mixing this with quantum.. this is a biotech stock

QSI quantom stocks will bleed tmrw as Jenson said technology is 30 years away. So the money will flow in this one as this has the technology and now the investors

QSI Quantum-Si (QSI): Revolutionizing Protein Sequencing

Quantum-Si (QSI) is a biotech innovator focused on next-generation protein sequencing, a growing field with immense potential in biological research, diagnostics, and drug discovery. By offering a scalable and cost-effective platform, QSI aims to transform how proteins are analyzed, much like DNA sequencing did for genomics.

Why Watch QSI?
• Disruptive Technology: Their platform could revolutionize proteomics, a market projected to grow significantly in the coming years.
• Growing Demand: Protein sequencing is critical for advancing precision medicine and drug development.
• Catalysts: Strong partnerships and adoption could drive long-term growth.